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ABSTRACT
Attrition within the CD4 T cell compartment, high viremia, and a cytokine storm characterize the early days after HIV infec-
tion. When the first emerging HIV-specific CD8 T cell responses gain control over viral replication it is incomplete, and clear-
ance of HIV infection is not achieved even in the rare cases of individuals who spontaneously control viral replication to nearly
immeasurably low levels. Thus, despite their partial ability to control viremia, HIV-specific CD8 T cell responses are insuffi-
cient to clear HIV infection. Studying individuals in the first few days of acute HIV infection, we detected the emergence of a
unique population of CD38 CD27 CD8 T cells characterized by the low expression of the CD8 receptor (CD8dim). Interest-
ingly, while high frequencies of HIV-specific CD8 T cell responses occur within the CD38 CD27 CD8dim T cell population,
the minority populations of CD8bright T cells are significantly more effective in inhibiting HIV replication. Furthermore, the fre-
quency of CD8dim T cells directly correlates with viral load and clinical predictors of more rapid disease progression.We found
that a canonical burst of proliferative cytokines coincides with the emergence of CD8dim T cells, and the size of this population
inversely correlates with the acute loss of CD4 T cells. These data indicate, for the first time, that early CD4 T cell loss coin-
cides with the expansion of a functionally impaired HIV-specific CD8dim T cell population less efficient in controlling HIV
viremia.
IMPORTANCE
A distinct population of activated CD8 T cells appears during acute HIV infection with diminished capacity to inhibit HIV rep-
lication and is predictive of viral set point, offering the first immunologic evidence of CD8 T cell dysfunction during acute in-
fection.
Immense levels of human immunodeficiency virus (HIV) repli-cation during the first days of infection are accompanied by
dramatic changes in the immune system that may determine the
quality of the subsequent immune response and ability to control
HIV replication (1). The acute destruction of over half of the
body’smemoryCD4T cells (2) is accompanied by changes in the
immune system, including a drop in the B cell compartment and a
major innate cytokine storm (3). Subsequent development of the
adaptive HIV-specific CD8 T cell response exerts selection pres-
sure on the virus, forcing it to evolve to evade immune recognition
and resulting in a lower level and semistable viral set point (4, 5).
The level of the early viral set point is highly predictive for long-
term disease outcome (6, 7), supporting the notion that the earli-
est events shaping the T cell responses are setting the stage for
disease progression. Indeed, some individual HIV-specific CD8
T cell responses during acute HIV infection have been identified
to dictate long-term disease outcome (8, 9).
However, while the first emerging HIV-specific CD8 T cell
responses are able to gain initial control over viral replication,
CD8 T cell-mediated control is incomplete, immunological
clearance of HIV infection is never observed, and viral replication
persists (10). This is partially due to HIV’s ability to escape from
CD8 T cell targeted epitopes (11, 12), resulting in either the lack
of recognition or generation of de novo CD8 T cell responses
against the variant epitope (13).
In the best (but rare) cases,HIV-specificCD8T cell responses
are able to effectively control viral replication to nearly immeasur-
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ably low levels. However, even then HIV cannot be cleared, and
the ongoing fight between virus and T cells leads to a deterioration
and exhaustion of the CD8 T cell responses (14–16). This ex-
haustion is characterized by a hierarchical loss of functions and
significant changes in the surface receptors, including the upregu-
lation of inhibitory receptors such as programmed death 1 (PD1).
Thus, besides the generation of the large breadth and magnitude
of CD8 T cell responses, the adaptive immune response appears
to suffer from insufficient effector function after acute HIV infec-
tion that can be explained neither by exhaustion nor CD8 T cell
escape. Here, we assessed HIV-infected individuals at the earliest
phase of acute infection to determinewhether the failure tomount
effectiveHIV-specific CD8T cell responses can be traced to early
immunological changes and describe a population of CD8 T
cells that is associated with a lack of subsequent control.
MATERIALS AND METHODS
Study participants. Twenty-four HIV-1 acutely infected participants
identified from the RV217 early-capture HIV cohort were selected based
on preinfection sample availability and at least two time points sampled
after infection and prior to peak viremia. RV217 is amulticenter, nonran-
domized clinical observational study designed to describe the biological
characteristics of acute HIV-1 infection in high-risk volunteers from Af-
rica and Southeast Asia. Acute HIV-1 infection was determined from
twice-weekly blood draws of at-risk populations using a nucleic acid test,
the Aptima HIV-1 RNA qualitative assay (Hologic Gen-Probe Inc., San
Diego, CA, USA), and confirmed by enzyme linked immunoassays and
Western blotting after the advent of detectable antibodies. HIV-1 viral
load was determined at every study visit with longitudinal samples using
the Abbott real-time HIV-1 assay with a detection limit of 40 HIV RNA
copies/ml (Abbott Laboratories, Abbott Park, IL, USA). The HIV-1 viral
set point was defined as the average of all viral load measurements be-
tween day 80 and day 365 in the absence of treatment, and it required at
least two measurements. Two study participants were considered to have
amissing set point viral load due to one individual initiating antiretroviral
therapy (ART) at day 35 and the other having only one measurement
available after day 80 prior to ART initiation; therefore, they were ex-
cluded from analysis with disease progression. Lymphocyte immunophe-
notyping was performed on fresh whole blood using the single-platform
BD Multiset TruCount method to determine absolute counts and per-
centages (BD Biosciences, San Jose, CA, USA). Table 1 summarizes pa-
tient demographics. CD8 T cell evaluation was completed through a
median of 54 days for all participants with an average of 7 time points
analyzed for the 13 East Africans and 11 Southeast Asians. One individual
initiated antiretroviral therapy prior to the establishment of set point
HIV-1 viral load.
Ethics statement. All individuals participating in this study provided
written informed consent. Ethical approval was obtained from institu-
tional review boards in each country as well as the Human Subjects Pro-
tection Branch at the Walter Reed Army Institute of Research, which
approved the overall protocol.
Phenotypic analysis.One hundred sixty-seven cryopreserved periph-
eral blood mononuclear cell (PBMC) samples of 24 individuals were
thawed and used for this study. Cells were washed in serum-free medium
and stainedwith Live/Dead fixable aqua (Life Technologies, Grand Island,
NY, USA) to exclude nonviable cells. PBMC then were washed with stain-
ing buffer containing 0.5% bovine serum albumin (BSA)–0.01% azide
and stained with 2 panels of monoclonal antibodies for polychromatic
flow-cytometric analysis. Antibodies used included CD4 Qdot605 (clone
TABLE 1 RV217 patient demographics
Patient ID Gender Age (yr) Country
CD4 T cell
nadir (cells/l)
Time to peak
VLa (days)
Peak VL (log10
copies/ml)
Set point VLb
(log10 copies/ml)
10220 F 33 Uganda 796 18 5.49 3.69
10428 F 27 Uganda 421 10 6.92 4.08
10435 F 18 Uganda 392 14 6.74 3.52
20225 F 24 Kenya 819 9 7.99 4.28
20263 F 20 Kenya 462 11 8.20 2.52
20337 F 24 Kenya 142 14 7.64 5.35
20355 F 24 Kenya 430 11 6.02 3.01
20368 F 18 Kenya 676 13 6.12 *
20509 F 24 Kenya 673 14 6.93 3.04
20511 F 24 Kenya 285 14 6.73 4.54
30112 F 25 Tanzania 884 18 7.50 4.38
30124 F 24 Tanzania 464 14 6.76 4.83
30190 F 25 Tanzania 511 11 7.34 5.96
40007 M 25 Thailand 406 15 7.31 5.35
40061 F 48 Thailand 312 14 5.79 *
40094 M 19 Thailand 866 16 6.40 4.64
40100 M 18 Thailand 467 10 8.46 5.22
40123 M 23 Thailand 616 14 6.24 4.47
40168 MtFc 25 Thailand 444 11 6.66 5.28
40250 M 35 Thailand 522 19 6.67 4.83
40257 MtF 18 Thailand 370 10 7.35 5.39
40265 M 23 Thailand 476 12 6.49 4.83
40353 M 21 Thailand 516 17 5.81 3.60
40363 MtF 29 Thailand 576 14 6.86 4.77
Average 25 522 13 6.85 4.44
a Peak indicates the true peak; VL indicates HIV-1 load (copies/ml).
b Set point VL is the average of all measured viral loads between day 80 and day 365 in the absence of treatment (requiring at least two measurements). An asterisk indicates that a
set point cannot be defined because of treatment.
c MtF, male-to-female transgender.
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S3.5), CD8a phycoerythrin (PE)-TR (clone 3B5), CD14 Tri-Color (clone
Tük4), and CD19 Tri-Color (clone SJ25-C1), all from Life Technologies.
CD3 allophycocyanin (APC)-eF780 (clone UCHT1), CD45R0 eFluor
650NC (clone UCHL1), andHLA-DR eFluor 450 (clone L243) were from
eBioscience, Inc., San Diego, CA, USA. CD27 peridinin chlorophyll pro-
tein (PerCP)-Cy5.5 and Alexa Fluor 700 (cloneO323), CD28 biotinylated
(clone CD28.2), CD45RA PerCP-Cy5.5 (clone HI100), CD57 fluorescein
isothiocyanate (FITC) (clone HCD57), CD62L Alexa Fluor 700 (clone
DREG-56), CD95Alexa Fluor 647 (cloneDX2), andCD127 BV421 (clone
A019D5) were all from BioLegend (San Diego, CA, USA). CD38 APC
(clone HB7), CD56 PE-Cy5 (clone B159), CD95 PE-Cy7 (clone DX2),
CCR5 (CD195) FITC (clone 2D7/CCR5), CCR7 (CD197) PE-Cy7 (clone
3D12), CXCR3 (CD183) PE (clone 1C6/CXCR3), and PD-1 (CD279) PE
(clone EH12.1) all were procured from BD Biosciences. 47 (ACT-1
clone) (NIH AIDS Research and Reference Reagent Program) was conju-
gated in-house with an eFluor 650 nanocrystal conjugation kit–amine-
reactive kit (eBioscience). After incubation, cells were washed with stain-
ing buffer and secondary Qdot 800 Streptavidin conjugate (Life
Technologies) was applied for CD28. Cells were washed, fixed with 2%
formaldehyde for 20min, washed again, and resuspended in staining buf-
fer. Samples then were acquired on an LSRII with a 4-laser configuration
(BD Biosciences) and analyzed using Flow Jo, version 9.7.5 (TreeStar,
Inc., Ashland, OR, USA).
Assessment of autologous HIV-specific CD8 T cell responses.
Founder viruses of three study participants were deduced from plasma
from the first time point preceding peak viremia with greater than 10,000
copies/ml following full-length single-genome amplification sequencing
using Sanger technology as described elsewhere (17). Autologous overlap-
ping peptides (18mer overlapping by 10 amino acids) were synthesized on
the basis of the viral sequence for each individual. Five peptide pools then
were generated forGag, Env,Nef, Pol, and accessory proteins. PBMCwere
thawed, counted, and plated as described above. Cells were stimulated in
the presence of 3 g/ml HIV peptide pools, costimulatory antibodies
CD28/CD49d and CD107a FITC (clone H4A3) (BD Biosciences), and
incubated at 5% CO2 at 37°C for 6 h. Brefeldin A and monensin were
added 2 h after stimulation. Cells were processed as described above.
Antibodies include CD14 Tri-Color (clone Tük4) and CD19 Tri-Color
(clone SJ25-C1), both from Life Technologies, CD38 APC (clone HB7),
CD56 PE-Cy5 (clone B159), CD197 PE-Cy7 (clone 3D12), and HLA-DR
APC-H7 (clone L243), all from BD Biosciences, CD45RO eFluor 650NC
(clone UCHL1) from eBioscience, and CD27 AL700 (clone O323) from
BioLegend. Cells then were washed, fixed in 2% formaldehyde, and per-
meabilized using Perm/Wash buffer (BD Biosciences). Cells then were
stained intracellularly with CD3 PE-TR (clone S4.1) and CD4 Qdot605
(clone S3.5) from Life Technologies, CD8 PerCP-Cy5.5 (clone SK1) and
interleukin-2 (IL-2) FITC (clone 5344.111) from BD Bioscience, and
gamma interferon (IFN-) eFluor 450NC (clone 4S.B3) from eBiosci-
ence. Cells were washed, resuspended in staining buffer, and acquired on
an LSRII flow cytometer (BD Biosciences).
Viral inhibition assay. PBMC from six patients identified in early
acute infectionwere sorted using a FACSAria SORP (BDBiosciences) into
CD4, CD8bright, and CD8dim T cells. Sorted cells were rested overnight at
37°C in RPMI containing 20% fetal bovine serum (FBS), IL-2 (50 IU/ml),
and IL-7 (5 ng/ml) in preparation for a modified viral inhibition assay as
previously described (18). The target cells (autologousCD4T cells) were
infected with a nevirapine-resistant virus at a multiplicity of infection
(MOI) of 0.01 for 2 h. Excess virus was washed off and 100,000 cells were
added to a 96-well plate in RPMI–10% fetal calf serum (FCS). Effector
cells (CD8bright and CD8dim T cells) were added to the targets at a ratio of
1:1. Nevirapine (NIH AIDS Reagent Program) was added to cultures on
day 0 at a concentration of 10 g/ml from a stock solution of 0.1 mg/ml.
Supernatant was removed 3, 5, and 7 days postinfection and frozen at80
before quantitative PCR (qPCR).
Soluble factor analysis. The cytokine levels of IL-2, IL-15, and IL-21
were assessed using a standard Luminex multiplexed bead system (Mil-
liplex) according to the manufacturer’s instructions and as previously
described (19). Results obtained from the Bio-Plex system were analyzed
automatically by the Bio-Plex Manager software program (Bio-Rad Lab-
oratories Inc., Hercules, CA, USA) using a (5PL-fit) standard curve de-
rived from recombinant cytokine and chemokine standards. IL-7 was
quantified from longitudinal citrate plasma samples by electrochemilumi-
nescent detection enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s protocol (Meso Scale Discovery, Rockville, MD).
Briefly, samples were diluted 1:2 in assay buffer and loaded onto the MSD
plate in duplicate along with an 8-point, 4-fold standard curve, also in dupli-
cate. After 2 h, plates were washed, and detection antibody bound to an elec-
trochemiluminescent label was added for 2 h. Plates were washed again and
read buffer added before the image was captured using a Meso QuickPlex
SQ120 imager and analyzed with DiscoveryWorkbench 4.0 software.
Statistical analysis. Statistical analysis was performed using Graph
Pad Prism software version 6.0a for Mac OS X (GraphPad Software, La
Jolla, CA, USA), JMP version 10.0.0, and SAS v9.3 (SAS, Cary, NC, USA).
The standard score (Z score) for each analyte at each time point was
calculated as sample measurement minus mean at baseline divided by
standard deviations at baseline. Analysis of immunologic variables before
and after infection was completed using the Friedman test for matched
nonparametric data. Comparisons between groups were performed using
the nonparametric Mann-Whitney U test or Wilcoxon method for con-
tinuous data. Correlations between continuous outcomes were deter-
mined by Spearman’s rank correlation. For predictive associations of set
point HIV viral load, linear regression models were generated. Assessing
model fit for maximumCD8dim CD38CD27 T cell frequency revealed
two observations with a high Cook’s distance, and models were fit with
and without these observations. Statistical significance was assessed at the
0.05 level.
RESULTS
Acute emergence of HIV-specific CD8 T cells with a unique
phenotype. To investigate the limited ability of HIV-specific
CD8 T cells to completely control viremia during acute HIV
infection, we studied a prospective cohort of high-risk HIV-unin-
fected individuals fromEast Africa and Thailand (RV 217/ECHO)
undergoing twice-weekly nucleic acid testing (Aptima HIV-1
RNAqualitative assay) to identify individuals in the earliest period
after HIV infection (20). Twenty-four participants with extensive
peripheral blood sampling before infection and also prior to peak
HIV viral load were included in this study. Patient characteristics
and demographics are shown in Table 1. Viral load peaked on
average 13 days after the first reactive HIV RNA test and ranged
from5.49 log10 to 8.46 log10HIVRNAcopies/ml, with amedian of
6.7 log10 HIV RNA copies/ml. Viral set point occurred an average
of 41 days after peak and ranged from 2.52 log10 to 5.96 log10 HIV
RNA copies/ml. The initial CD4 count dropped from 855 to 472
cells/l (range, 142 to 884 cells/l) within 20 days from the first
reactive HIV RNA test. In contrast, the CD8 T cell count in-
creased from 500 cells/l (range, 209 to 1,150 cells/l) to 1,413
cells/l (range, 558 to 3,581 cells/l; P  0.001) (Fig. 1). The
flow-cytometric assessment of CD8 T cell phenotype before and
during acute HIV infection demonstrated dramatic and synchro-
nized changes to T cell surface receptor expression in parallel to
HIV viral load kinetics (Fig. 2 and 3A). In particular, CD8 T cell
activation indices coincided with HIV expansion and were asso-
ciated with the loss of IL-7 receptor (CD127) expression. How-
ever, we found most phenotypic markers did not occur singularly
on CD8 T cells; rather, we noted a shift or emergence of specific
clusters of CD8 T cell populations (Fig. 3B). In particular, we
noted a profound contraction of the CD28CD127CD8T cell
population and a corresponding increase of activated CD8 T
CD8dim in Acute HIV Infection
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cells with the CD38 HLADR phenotype. The most dramatic
changes were observed with the emergence of a CD8 T cell pop-
ulation characterized by the CD38 CD27 phenotype (Fig. 3B
and C), which appeared a median of 8 days after the detection of
HIV-1RNA in the periphery, closely followed viral load trajectory,
but it continued to be significantly elevated for the remainder of
the study (P  0.001) (Fig. 3D). This population, clearly distin-
guishable by the lower expression of the CD8 receptor (CD8dim)
(Fig. 3E), was absent prior to HIV infection. Taken together, we
found dramatic harmonized changes within theCD8T cell com-
partment characterized by the emergence of a unique CD38
CD27 CD8dim T cell subset.
Early changes in the CD8 T cell compartment is associated
with loss of CD4 T helper cells. Given the dramatic loss of pe-
ripheral CD4 T cells during acute HIV infection, we wondered
whether the emergence of this aberrant CD8 T cell population is
associated with the early changes in the CD4 T cell compart-
ment. While CD4 and CD8 T cell homeostasis are believed to
be rather independent (21), we found that the CD4 nadir, defined
as the minimum CD4 T cell absolute count in acute HIV infec-
tion prior to day 80, was inversely correlated with HIV viral load
(rho 	 0.478, P 	 0.024) (Fig. 4A) and HIV levels of CD38
CD27 CD8dim T cells (rho 	 0.495, P 	 0.014) (Fig. 4B) at a
time when viral decline is most profound, suggesting that at least
in part the damage to the CD4 T cell compartment is associated
with the emergence of this uniqueCD8Tcell phenotype. Indeed,
we observed inverse trajectories of CD4 absolute counts and
CD38 CD27 CD8dim T cell frequency longitudinally during
acute HIV-1 infection (Fig. 4C). To further understand the link
between CD4 loss and CD8 T cell proliferation, we next deter-
mined plasma levels of proliferative cytokines, including IL-2,
IL-7, IL-15, and IL-21 (22).Whilewe foundnodirect link between
a single cytokine and the emergence of CD8dim T cells, we never-
theless observed that a canonical burst of the cytokines preceded
the expansion of the CD38 CD27 CD8dim T cell subset (Fig.
4D). Thus, our data suggest that the extent of damage to the CD4
T cell compartment during acute HIV infection may in part con-
tribute to the development of unique phenotypes of activated
CD8 T cells.
High frequency of HIV-specific CD8 T cells are CD38
CD27 CD8dim T cells.We next investigated whether the expan-
sion of the CD8dim population is virus specific or a nonspecific
alteration within the CD8 T cell compartment. Given the vast
amount of HIV sequence diversity and recombinant forms in par-
ticular in the East-African population, we sequenced the founder
virus from three study participants and generated autologous pep-
tide sets spanning the entire HIV proteome to accurately deter-
mine the contribution of virus-specific CD8 T cells to the in-
crease of CD38 CD27 CD8dim T cells (23, 24). In all three
longitudinally studied individuals, we observed the emergence of
HIV-specific CD8 T cells, determined by either degranulation
(CD107a) or cytokine production (IFN- or IL-2), early in acute
HIV infection with various kinetics and specificities (Fig. 5A).
While the majority of the responses increased over time, there
were some individual responses targeting more variable segments
of the viral proteome that showed an early expansion but then
declined over the initial period of infection, as previously de-
scribed (23, 24). Interestingly, both CD8bright and CD8dim T cells
contained HIV-specific responses, yet a higher frequency of HIV-
specific CD8 T cell responses are within the CD8dim population
(Fig. 5B). It is important to note that no specific trends or patterns
emerged with regard to the epitope targeting between the
CD8bright and CD8dim T cells. We further characterized the HIV-
specific CD8 T cell population and found that they demon-
strated lower expression of CD27, with an effector memory phe-
notype (CCR7 CD45RO), and were consistently HLADR
(Fig. 5C). Coordinated expression patterns of CCR7, CD27,
CD38, CD45RO, and HLA-DR were significantly different be-
tweenHIV-specific CD8bright and CD8dim T cells (P 0.001) (Fig.
5D). Interestingly, the only distinct subset we observed within this
homogenous virus-specific CD8 T cell population was the
CD38 CD27 CD8dim T cell population (Fig. 5E).
CD38 CD27 CD8dim T cells are inefficient in control of
viral replication. We next asked whether the two phenotypically
distinct CD8 T cell populations with HIV-specific functional
activity were equally capable of controlling HIV viremia. There-
fore, we purified CD8bright and CD8dim T cells from 6 patients
immediately following peak viremia (average of 4 days after peak
viremia [14 to 21 days following the first positive HIV determina-
tion]), where the most precipitous viral load decline occurs. We
simultaneously activated and infected autologous CD4 T cells as
target cells with nevirapine-resistant virus in culture (Fig. 6A).
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FIG 3 Longitudinal changes of surface maker expression on CD8 T cells during acute HIV infection. (A) Relative changes (Z-score) of surface markers on
CD8 T cells during acute HIV infection. Average viral loads are depicted as red-segmented lines from the first RNA-positive HIV nucleic acid test. (B) Color
intensitymap of themost dramatic shifts within the CD8T cell populations during acuteHIV infection. Populations are shown as amedian frequency of CD8
T cells based on specific combinations of receptors from green (no expression) to red (
40% expression). (C) Successive pseudocolor plots from CD8 T cells,
demonstrating CD38 against CD27 longitudinally, through acute HIV-1 infection and the emergence of a CD38CD27 population in a representative donor.
(D) Expansion of cells in association with viral loads. (E) Concatenated polychromatic plot of CD8 over time depicts the emergence of the CD38 CD27
population as a CD8dim subset.
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Immunofluorescently stained and sorted CD8bright and CD8dim T
cells were added as effector cells at a ratio of 1:1. Strikingly, after 5
days of infection, we found that the CD8bright T cell population
was significantlymore efficient at viral inhibition than the CD8dim
T cell population (65% versus 45%, respectively; P 	 0.016) de-
spite the higher frequency of HIV-specific CD8 T cells observed
in the CD8dim T cell population (Fig. 6B). We next assessed
whether this population shows any association with levels of HIV
viral load. Indeed, we found that 7 days after peak viremia the
frequency of CD38 CD27 CD8dim T cells was positively associ-
atedwith viral load (rho	 0.591, P	 0.004) (Fig. 6C). Examining
absolute CD4 T cell counts at contemporaneous time points
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revealed a trend toward an inverse relationship with the frequency
of CD38CD27CD8dim T cells (rho	0.382, P	 0.079) (Fig.
6D). The maximum frequency of CD38 CD27 CD8dim T cells,
which occurred an average of 18 days after the first positive HIV-1
nucleic acid test, was significantly correlated with set point viral
load (Spearman rho 	 0.498, P 	 0.018). Fitting a linear regres-
sion model with the maximum frequency of CD38 CD27
CD8dim T cells as a predictor yielded a positive relationship with a
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marginally significant P value for set point viral load (beta	 0.03,
P 	 0.066). Further examination of model fit revealed two data
points with a large Cook’s distance. Removing these potential out-
liers and refitting the model yielded a similar result with a signif-
icant P value (beta 	 0.04, P 	 0.003) (Fig. 6E). In addition, the
frequency of less functional CD38 CD27 CD8dim T cells was
positively associated with higher set-point CD4 T cell activation
(rho	 0.448, P	 0.037) (Fig. 6F), another marker of rapid HIV
disease progression. Taken together, these data suggest that the
loss of CD4 T cells in acute HIV infection drives the emergence
of a suboptimal CD8 T cell population that is less capable of
controlling viral replication andmay reflect faster disease progres-
sion.
DISCUSSION
The efficacy of CD8T cell-mediated control ofHIV replication is
one of the leading underlying mechanisms that determine the
long-term control and disease progression in the absence of anti-
retroviral therapy. However, in most cases of HIV-infected indi-
viduals, CD8T cells are incapable of achieving durable control of
HIV replication, and there is no documented case of natural clear-
ance or cure from HIV infection. Here, we found that the ineffi-
ciency of CD8 T cells to control viral replication is associated
with the emergence of a unique CD8 T cell phenotype. These
CD8 T cells are characterized by the expression of CD38
CD27 and low expression of the CD8 T cell receptor. While
these cells harbor a high frequency of HIV-specific CD8 T cell
responses, they are less efficient at suppressing viral replication.
Moreover, we found that the frequency of this particular pheno-
type was associated with viral loads and markers for disease pro-
gression, suggesting that the generation of CD8 T cells with the
aberrant phenotype greatly influences long-term disease out-
come.
CD8 T cells with low expression of the CD8 receptor have
been observed previously in persistent viral infections and de-
scribed to have inefficient cytotoxic activity (25–27). Indeed, the
presence of a CD8dim population also has been described in
chronic HIV infection and associated with poor disease outcome
(28). The physiologic role for CD8dim T cells currently is un-
known. It has been speculated that either antigen persistence
drives the development of an inefficient cellular T cell population
or that these cells emerge as a regulatory population that controls
the intensity of ongoing cytolytic and tissue-damaging activity
(29). While both scenarios have been described in chronic infec-
tion and later stages of viral infections, the emergence of these cells
during the acute phase of HIV infection is surprising and has been
described previously only in simian immunodeficiency virus
(SIV) infection (26). In particular, as a large fraction of HIV-
specific CD8 T cell responses are contained in the CD8dim pop-
ulation, their overall contribution to the control of viral replica-
tion appears to be relatively minor. Indeed, the frequency of these
CD8T cells positively correlates withHIV viral load and portend
aworse prognosis for disease progression. A potential explanation
for the emergence of a dysfunctional CD8T cell population is the
lack of CD4 help during the acute phase of HIV infection due to
the massive destruction in the CD4 T cell compartment. While
studies have demonstrated that efficient CD8 T cell responses
can be primed in the absence of CD4 help (reviewed in reference
30), CD4-mediated helper signals nevertheless often are required
for the generation of long-lived, functional memory CD8 T cell
responses. Indeed, it has been described that the lack of CD4 T
cell help in the acute phase of infections can influence the fre-
quency, phenotype, and function of CD8 T cell responses (31,
32). Here, we found that the size of the CD8dim T cell population
was associated with the early CD4 T cell nadir, suggesting that
the loss of early CD4 T cells and their helper function is involved
in the emergence of the unique CD8T cell populations. Previous
studies have already suggested that a low acute CD4 nadir is asso-
ciated with a poor long-term disease outcome (33), but a link to
the CD8 T cell population has not been established. A further
indicator that insufficient CD4 help is driving the CD8dim pheno-
type is the activated CD8 T cell phenotype (CD38) but lack of
CD27 expression. Previous studies suggested that CD8 T cells
primed in the absence of CD4 help lack the expression of CD27,
which renders them inefficient to expand in the recall phase of the
response (34, 35).
Thus, our data suggest an explanation for differences in prog-
nosis as estimated here by viral load set point and CD4 activation
in which CD4 count loss and canonical bursts of proliferative
cytokines drive the expansion of a less functional CD8 T cell
population that is not able to fully suppress viremia. Furthermore,
our data support the notion that ART treatment during early
acute HIV infection leads to an overall improvement of CD8 T
cell function by preventing or limiting the emergence of the
CD8dim population and ultimately permit durable control of HIV
with future treatment interruptions due to a more dominant and
functional CD8bright HIV-specific immune response (36–39).
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